{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:07:56Z","timestamp":1791277676939,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.tem.2004.05.005","type":"journal-article","created":{"date-parts":[[2004,6,15]],"date-time":"2004-06-15T19:32:24Z","timestamp":1087327944000},"page":"229-233","source":"Crossref","is-referenced-by-count":34,"title":["What's new with PTH in osteoporosis: where are we and where are we headed?"],"prefix":"10.1016","volume":"15","author":[{"given":"Clifford J","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2004.05.005_BIB1","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/en.2003-1038","article-title":"Insulin-like growth factor I and calcium balance: evolving concepts of an evolutionary process","volume":"144","author":"Rosen","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2004.05.005_BIB2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","article-title":"Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1\u201334) therapy in women with severe osteoporosis","volume":"27","author":"Hodsman","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.tem.2004.05.005_BIB3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.280.12.1067","article-title":"Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1\u201334): a randomized controlled trial","volume":"280","author":"Finkelstein","year":"1998","journal-title":"J.A.M.A."},{"key":"10.1016\/j.tem.2004.05.005_BIB4","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB5","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1359\/jbmr.2001.16.9.1665","article-title":"Human parathyroid hormone 1\u201334 reverses bone loss in ovariectomized mice","volume":"16","author":"Alexander","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/jbmr.5650090619","article-title":"Anabolic effect of high doses of human parathyroid hormone (1\u201338) in mature intact female rats","volume":"9","author":"Jerome","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/jbmr.5650110509","article-title":"Bone-selective analogs of human PTH(1\u201334) increase bone formation in an ovariectomized rat model","volume":"11","author":"Lane","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB8","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1210\/jc.84.10.3757","article-title":"Daily treatment with human recombinant parathyroid hormone-(1\u201334), LY333334, for 1 year increases bone mass in ovariectomized monkeys","volume":"84","author":"Brommage","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2004.05.005_BIB9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s001980070047","article-title":"Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques","volume":"11","author":"Sato","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.tem.2004.05.005_BIB10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","article-title":"Intermittently administered human parathyroid hormone(1\u201334) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys","volume":"16","author":"Burr","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(00)00430-0","article-title":"Treatment with human parathyroid hormone (1\u201334) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)","volume":"28","author":"Jerome","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.tem.2004.05.005_BIB12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1359\/jbmr.2002.17.5.808","article-title":"Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice","volume":"17","author":"Iida-Klein","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB13","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1172\/JCI116483","article-title":"Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol","volume":"91","author":"Shen","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2004.05.005_BIB14","first-page":"448","article-title":"Bone effects in mice of ovariectomy and recombinant human PTH 1\u201334 are highly strain dependent","volume":"23","author":"Zeng","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.tem.2004.05.005_BIB15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0009-9236(97)90169-7","article-title":"Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1\u201384)] in healthy postmenopausal volunteers","volume":"61","author":"Schwietert","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2004.05.005_BIB16","first-page":"253","article-title":"A comparison of the pharmacokinetics of PTH in healthy young and osteoporotic subjects","volume":"8S","author":"Fraher","year":"1993","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1210\/jc.82.3.900","article-title":"Parathyroid hormone-related protein-(1\u201336) is biologically active when administered subcutaneously to humans","volume":"82","author":"Henry","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2004.05.005_BIB18","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2004.05.005_BIB19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB20","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial","volume":"15","author":"Lane","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.tem.2004.05.005_BIB21","first-page":"S54","article-title":"Effects of discontinuation of teriparatide treatment on cortical bone in postmenopausal women with osteoporosis","volume":"18","author":"Bogado","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8529(02)00024-5","article-title":"Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures","volume":"31","author":"Guyatt","year":"2002","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.tem.2004.05.005_BIB23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","article-title":"Effects of teriparatide [recombinant human parathyroid hormone (1\u201334)] on cortical bone in postmenopausal women with osteoporosis","volume":"18","author":"Zanchetta","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00198-002-1312-0","article-title":"Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis","volume":"14","author":"Rehman","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.tem.2004.05.005_BIB25","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2004.05.005_BIB26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1210\/jc.84.5.1562","article-title":"On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism","volume":"84","author":"Dempster","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2004.05.005_BIB27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial","volume":"102","author":"Lane","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2004.05.005_BIB28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1210\/jc.82.2.620","article-title":"A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis","volume":"82","author":"Hodsman","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2004.05.005_BIB29","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.tem.2004.05.005_BIB30","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of PTH and alendronate alone or in combination in post-menopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2004.05.005_BIB31","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2004.05.005_BIB32","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1210\/jc.85.6.2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2004.05.005_BIB33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S8756-3282(98)00024-6","article-title":"Effects of a weekly injection of human parathyroid hormone (1\u201334) and withdrawal on bone mass, strength, and turnover in mature ovariectomized rats","volume":"22","author":"Okimoto","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.tem.2004.05.005_BIB34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s001980050151","article-title":"Effect of an intermittent weekly dose of human parathyroid hormone (1\u201334) on osteoporosis: a randomized double-masked prospective study using three dose levels","volume":"9","author":"Fujita","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.tem.2004.05.005_BIB35","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1210\/jc.85.9.3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2004.05.005_BIB36","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1210\/en.2002-220221","article-title":"Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos","volume":"143","author":"Demiralp","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2004.05.005_BIB37","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1359\/jbmr.2002.17.9.1570","article-title":"Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone","volume":"17","author":"Bikle","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.tem.2004.05.005_BIB38","first-page":"S157","article-title":"Gene array analysis of the bone effects of raloxifene and alendronate show that alendronate strongly inhibits the expression of bone formation marker genes","volume":"17","author":"Onyia","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.tem.2004.05.005_BIB39","first-page":"S24","article-title":"PTH [1\u201334] enhances experimental fracture healing","volume":"18","author":"Alkhiary","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.tem.2004.05.005_BIB40","first-page":"S540","article-title":"Oral delivery of PTH analogs by a solid dosage formulation","volume":"16","author":"Mehta","year":"2001","journal-title":"J. Bone Miner. Res."}],"container-title":["Trends in Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327600400089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327600400089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T03:30:20Z","timestamp":1549510220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104327600400089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S104327600400089X"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2004.05.005","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}